Shots:

• Lilly enters into a non-exclusive commercialization agreement with DexCom to integrate Dexcom’s CGM device in both the pen- and pump-based platforms- designed to improve diabetes management
• The collaboration will integrate connected insulin delivery devices- software and analysis to aid patients with T1D and T2D and provide personalized information to HCPs to simplify diabetes management
• The pen-based platform is to integrate personalized data from a prefilled- disposable insulin pen with data from glucose-sensing technologies into an app while the pump-based platform is used to integrate insulin pump- CGM and a handheld controller or an app controlling the system to automate insulin dosing

Click here to­ read full press release/ article | Ref: Eli Lilly | Image: cbs4indy